talipexole talipexole talipexole (b-ht920, domnin) is a dopamine agonist that is marketed as a treatment for parkinson's disease in japan by boehringer ingelheim; it was introduced in 1996. as of december 2014 it was not approved for marketing in the us nor in europe. talipexoleclinical datatrade namesdominother namesalefexoleahfs/drugs.cominternational drug namesroutes ofadministrationoralatc codenonelegal statuslegal status in general: ℞ (prescription only) identifiers iupac name 6-allyl-5,6,7,8-tetrahydro-4h-thiazoloazepin-2-amine cas number101626-70-4 ndihydrochloride: 36085-73-1 36085-73-1 ypubchem cid5374iuphar/bps5442chemspider5181 nunii7am2j46z1ydihydrochloride: 9r6e1d8h1o ychemblchembl1289023 ncomptox dashboard (epa)dtxsid8046321 chemical and physical dataformulac10h15n3smolar mass209.31 g·mol−13d model (jsmol)interactive imagedihydrochloride: interactive image smiles n1c2c(sc1n)ccn(cc2)c\c=cdihydrochloride: c=ccn1ccc2=c(cc1)sc(=n2)n inchi inchi=1s/c10h15n3s/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2h,1,3-7h2,(h2,11,12) nkey:dhssdedrbuktqy-uhfffaoysa-n n ny (what is this?) (verify) talipexole is a d2 dopamine receptor agonist and interacts both pre- and post-synaptic receptors. it also is an α2-adrenergic agonist. the main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints. in 2008 the japanese ministry of health, labour, and welfare mandated that boehringer add a warning to the label concerning the risk of sudden onset of sleep.: 15 synthesis synthesis: patents: sino: the n-alkylation of azepan-4-one (1) with allyl bromide in the presence of potassium carbonate gives 1-allyl-azepan-4-one (2). this is halogenated with molecular bromine in acetic acid to give 1-allyl-5-bromohexahydro-4-azepinone (3). the last step involves cyclization with thiourea (4) in refluxing ethanol, completing the synthesis of talipexole (5).